Skip to main content

Table 3 Multivariate analysis

From: The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study

 

PFS

OS

Multivariate

Multivariate

HR

95% CI

p value

HR

95% CI

p value

ECOG

 0 or 1

  

0.003

  

< 0.001

 2 or 3

1.907

1.245–2.921

 

2.607

1.666–4.080

 

Diagnosis

   

 NSCLC

  

0.062

   

 Othersa

1.328

0.986–1.788

    

Stage

 III

  

0.025

  

0.103

 IV

2.605

1.130–6.004

 

2.332

0.842–6.461

 

Number of metastatic organ

 0 or 1

     

0.007

 ≥ 2

   

1.6

1.135–2.256

 

Number of treatment line

 1st

  

< 0.001

   

 2nd

2.035

1.410–2.939

< 0.001

   

 ≥ 3rd

1.885

1.269–2.800

0.002

   

Clinical trial

 Yes

     

0.001

 No

   

1.829

1.266–2.641

 

Antibiotics during ICI

 No

  

0.037

   

 Yes

0.7

0.501–0.978

    

Antibiotics before ICI

 No

  

0.001

  

0.001

 Yes

1.715

1.264–2.326

 

1.785

1.265–2.519

 
  1. aMelanoma, Bladder cancer, Renal cell carcinoma, Head and Neck cancer, Stomach cancer, Hepato cellular carcinoma, Esophageal cancer, Small cell lung cancer, Anal cancer, Cervical cancer, Colorectal cancer, Jejunal cancer, MUO, Ovarian cancer, Sarcoma
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us